Sleep Apnea – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Sleep Apnea – Drugs In Development, 2024 report and make more profitable business decisions.
Sleep apnea, a prevalent condition, involves the recurrent interruption and resumption of breathing during sleep. Two main types exist, obstructive and central sleep apnea. Obstructive sleep apnea occurs when the upper airway is frequently blocked, diminishing or halting airflow. Common risk factors include obesity, enlarged tonsils, and hormonal changes. Central sleep apnea results from the brain’s failure to send necessary signals for breathing. Health conditions affecting the brain’s control over airway and chest muscles contribute to this type. Diagnosis involves a sleep study, with treatments including continuous positive air pressure (CPAP) machines and lifestyle adjustments. Surgical intervention may be considered if initial treatments prove ineffective. Untreated sleep apnea can lead to cognitive difficulties and serious health issues.
The Sleep Apnea drugs in development market research report provide comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Sleep Apnea | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 36 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Sleep Apnea therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Sleep Apnea pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Sleep Apnea treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aceragen IncApnimed Inc
Bayer AG
Bioprojet SCR
Brigham and Women's Hospital
Citrine (Shanghai) Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Enalare Therapeutics Inc
Evero Health Ltd
Idorsia Pharmaceutical Ltd
IGNIS Therapeutics Shanghai Co Ltd
Incannex Healthcare Ltd
Merck & Co Inc
Monash University
Mosanna Therapeutics AG
ResolutionRx Ltd
RespireRx Pharmaceuticals Inc
Shionogi-Apnimed Sleep Science LLC
Snoretox Pty Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
University of Chicago
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Sleep Apnea reports